BEACON HILL WEALTH MANAGEMENT LTD.’s Akebia Therapeutics AKBA Stock Holding History

BEACON HILL WEALTH MANAGEMENT LTD.’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.8K	Buy	+20,000	New	+$23.8K	0.02%	27

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

BEACON HILL WEALTH MANAGEMENT LTD.'s AKBA Position: Q2 2026 in Review

BEACON HILL WEALTH MANAGEMENT LTD. opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 20,000 shares worth $22.8K. The stake represents 0.02% of the portfolio and ranks #27 among its holdings.

96 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

BEACON HILL WEALTH MANAGEMENT LTD. held 20,000 shares of Akebia Therapeutics worth $22.8K as of Q2 2026.
Akebia Therapeutics was a new BEACON HILL WEALTH MANAGEMENT LTD. position in Q2 2026.
Akebia Therapeutics made up 0.02% of BEACON HILL WEALTH MANAGEMENT LTD.'s portfolio in Q2 2026, its #27 holding.
96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on BEACON HILL WEALTH MANAGEMENT LTD.'s 13F filing for Q2 2026, filed 11 Aug 2026.